Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy

Li, Mingjia; Zhao, Songzhu; Lopez, Gabrielle; Secor, Austin; Das, Parthib; Surya, Nitya; Grogan, Madison; Patel, Sandip; Chakravarthy, Karthik; Miah, Abdul; Spakowicz, Daniel; Tinoco, Gabriel; Li, Zihai; Wei, Lai; He, Kai; Bertino, Erin M.; Alahmadi, Asrar; Memmott, Regan M.; Kaufman, Jacob M.; Shields, Peter G.; Carbone, David P.; Presley, Carolyn J.; Owen, Dwight H.

doi:10.1007/s00262-023-03392-9

Cited by 4 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24,25 Unfortunately, NSCLC is often diagnosed in advanced stages, leading to poor prognosis. 26 which has been linked to the migration and invasion of nasopharyngeal carcinoma, was found to be upregulated in NSCLC patients at both the mRNA and protein levels. Patients with high TRIM11 expression had lower survival rates.…”

Section: Discussionmentioning

confidence: 99%

“…In China, lung cancer is the most common cancer and the leading cause of cancer‐related deaths 24,25 . Unfortunately, NSCLC is often diagnosed in advanced stages, leading to poor prognosis 26 . TRIM11, which has been linked to the migration and invasion of nasopharyngeal carcinoma, was found to be upregulated in NSCLC patients at both the mRNA and protein levels.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

Liang,

Li,

Zhang

et al. 2023

Clinical Respiratory J

View full text Add to dashboard Cite

Lung cancer is one of the leading causes of cancer‐related deaths worldwide, with non‐small cell lung cancer (NSCLC) being the most prevalent type. This study investigates the role of TRIM11 gene in NSCLC and its underlying mechanism. NSCLC patients were recruited from our hospital and showed upregulated TRIM11 mRNA and protein expressions. Patients with high TRIM11 expression had lower survival rates. TRIM11 gene was found to promote cell proliferation and reduce ROS‐induced ferroptosis in NSCLC. Additionally, TRIM11 gene induced AMPK expression and its regulation affected TRIM11's effects on cell proliferation and ferroptosis in NSCLC. IP analysis revealed that TRIM11 protein interacted with AMPK protein in NSCLC. These data confirmed that TRIM11 promotes cell proliferation and reduces ROS‐induced ferroptosis in NSCLC through AMPK. Hence, TRIM11 is a potential target for the treatment of NSCLC and other cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

Liang,

Li,

Zhang

et al. 2023

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…However, another study by Hu et al could not confirm this association [ 37 ]. Other potential biomarkers included a C-reactive protein >10 and decreased mean platelet volume change of ≤−0.2 fL, which were both associated with increased risk of irAEs [ 82 , 83 ].…”

Section: Biomarkersmentioning

confidence: 99%

“…, PD-L1 (rs4143815), and CTLA-4 (rs3087243, rs11571302, and r27565213) [72] GARBP, DSC2, BAZ2B, SEMA5A, and TYK2 SNPs [73] TMEM162 (rs541169) [34] MAPK1 (rs3810610), ADAD1 (rs17388568) [74] Negative predictor: UNG (rs246079) [72] miRNA-146a (rs2910164) CC genotype [75,76] PTPRC (rs6428474), IL6 (rs1800796) [74] OSBPL6, AGPS, RGMA, ANKRD42, PACRG, FAR2, ROBO1, GLIS3, PVT1, PACRG, PREX2, HLA-DRB1, HLA-DQA1, HLA-DQA2, and TNFAIP3 SNPs [73] No association: PDCD1 (rs2227981) [77] Positive predictor: SYK (rs7036417) [78] Other Frameshift neoantigen antibodies Predictive of irAE [79] ctDNA alteration CEBPA, FGFR4, MET, and KMT2B alterations: associated with irAE [80] RNA expression Positive predictor: LCP1 and ADPGK [56] PD-L1 expression Positive predictor: PD-L1 expression ≥50% [36,81] Not predictive [37] Negative predictor: PD-1 expression on CD4 + and CD8 + T-cells [58] Mean platelet volume change Negative predictor: decrease of ≤−0.2 fL [82] C-reactive protein Positive predictor: >10 [83] Note: If not specifically denoted, the biomarker is a positive predictor for irAE. Abbreviation: ctDNA, circulating tumor DNA; CTLA-4, cytotoxic T-lymphocyte associated protein 4; HLA, human leukocyte antigen; irAE, immune-related adverse event; PD(L)1, programmed cell death protein 1/programmed death-ligand 1; SNP, single-nucleotide polymorphism.…”

Section: Snpsmentioning

confidence: 99%

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors

Ponvilawan,

Khan,

Subramanian

et al. 2024

Cancers

View full text Add to dashboard Cite

Immune-related adverse events (irAEs) are the most common complication of immune checkpoint inhibitor (ICI) therapy. With the widespread use of ICIs in patients with solid tumors, up to 40% of the patients develop irAEs within five months of treatment, and 11% develop severe irAEs requiring interventions. A predictive test for irAEs would be a crucial tool for monitoring for complications during and after ICI therapy. We performed an extensive review of potential predictive biomarkers for irAEs in patients who received ICI therapy. Currently, only thyroid-stimulating hormone is utilized in common clinical practice. This is due to the unavailability of commercial tests and unclear predictive values from various studies. Given the lack of single strong predictive biomarkers, some novel approaches using composite scores using genomic, transcriptomics, cytokine levels, or clinical parameters appear appealing. Still, these have yet to be validated and incorporated into clinical practice. Further research conducted to validate the models before implementing them into real-world settings will be of the utmost importance for irAE prediction.

show abstract

“…Recently, Li et al undertook a retrospective analysis to investigate mean platelet volume (MPV), platelet count, survival rate, and risk of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). The results indicate a significant correlation between the alteration in MPV following one cycle of pembrolizumab treatment and both the overall survival and occurrence of irAEs in NSCLC patients (Li et al 2023 ). MPV can also serve as a convenient prognostic diagnostic marker for locally advanced non-small cell lung cancer (Pyo et al 2016 ; Sakin et al 2019 ).…”

Section: Introductionmentioning

confidence: 99%

TEP RNA: a new frontier for early diagnosis of NSCLC

Wang,

Dong,

Jin

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (LC), which is the leading cause of tumor mortality. In recent years, compared with tissue biopsy, which is the diagnostic gold standard for tumor diagnosis, Liquid biopsy (LB) is considered to be a more minimally invasive, sensitive, and safer alternative or auxiliary diagnostic method. However, the current value of LB in early diagnosis of LC is not ideal, so it is particularly important to study the changes in blood composition during the process of tumorigenesis and find more sensitive biomarkers. Purpose Platelets are a type of abundant blood cells that carry a large amount of RNA. In the LC regulatory network, activated platelets play an important role in the process of tumorigenesis, development, and metastasis. In order to identify predictive liquid biopsy biomarkers for the diagnosis of NSCLC, we summarized the development and function of platelets, the interaction between platelets and tumors, the value of TEP RNA in diagnosis, prognosis, and treatment of NSCLC, and the method for detecting TEP RNA of NSCLC in this article. Conclusion The application of platelets in the diagnosis and treatment of NSCLC remains at a nascent stage. In addition to the drawbacks of low platelet count and complex experimental processes, the diagnostic accuracy of TEP RNA-seq for cancer in different populations still needs to be improved and validated. At present, a large number of studies have confirmed significant differences in the expression of TEP RNA in platelets between NSCLC patients and healthy individuals. Continuous exploration of the diagnostic value of TEP RNA in NSCLC is of utmost importance. The integration of NSCLC platelet-related markers with other NSCLC markers can improve current tumor diagnosis and prognostic evaluation systems, providing broad prospects in tumor screening, disease monitoring, and prognosis assessment.

show abstract

Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy

Cited by 4 publications

References 38 publications

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

TRIM11 promotes cell proliferation of non‐small cell lung cancer through the inhibition of ferroptosis by AMPK

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors

TEP RNA: a new frontier for early diagnosis of NSCLC

Contact Info

Product

Resources

About